

# Suzanne Jones

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/900469/publications.pdf>

Version: 2024-02-01

9  
papers

859  
citations

1163117  
8  
h-index

1474206  
9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

1826  
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. <i>Nature Communications</i> , 2016, 7, 12624.	12.8	550
2	Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1764-1771.	1.6	149
3	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3263-3272.	7.0	61
4	Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 36-44.	7.0	32
5	Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. <i>Clinical Cancer Research</i> , 2021, 27, 1864-1874.	7.0	20
6	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group. <i>Clinical Cancer Research</i> , 2021, 27, 2416-2423.	7.0	18
7	A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. <i>Targeted Oncology</i> , 2021, 16, 569-589.	3.6	10
8	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. <i>JCO Precision Oncology</i> , 2021, 5, 1625-1638.	3.0	10
9	Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics. <i>JCO Precision Oncology</i> , 2021, 5, 1297-1311.	3.0	9